We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+10.27%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.02B
AUM Growth
+$67.6M
(+7.1%)
Cap. Flow
+$52.9M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
47.33%
Holding
173
New
45
Increased
25
Reduced
30
Closed
56
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$31.8M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$26.7M |
| 3 |
Zimmer Biomet
ZBH
|
+$24.4M |
| 4 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$22.7M |
| 5 |
Insmed
INSM
|
+$21.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$17.8M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$15.8M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$12.7M |
| 4 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$10.4M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.37% |
| 2 | Financials | 1.05% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Industrials | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sarepta Therapeutics
SRPT
$1.65B
| $76.2M | 7.48% |
2,558,478
-320,501
| -11% | -$10.1M |
|
2
Neurocrine Biosciences
NBIX
$18.2B
| $68.3M | 6.7% |
4,599,867
-19,500
| -0.4% | -$275K |
|
3
Talphera
TLPH
$67M
| $67.4M | 6.61% |
328,703
| – | – |
|
4
Vertex Pharmaceuticals
VRTX
$124B
| $44.5M | 4.37% |
470,142
-111,586
| -19% | -$7.82M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $43.6M | 4.28% |
507,488
+95,088
| +23% | +$7.23M |
|
|
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $42.3M | 4.15% |
301,333
+204,322
| +211% | +$22.7M |
|
|
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
| $41.2M | 4.04% |
12,339,444
+11,373,144
| +1,177% | +$26.7M |
|
|
QCOR
8
DELISTED
QUESTCOR PHARMA INC
QCOR
| $37M | 3.63% |
400,000
+371,400
| +1,299% | +$31.8M |
|
|
9
Insmed
INSM
$22.5B
| $36M | 3.53% |
1,800,000
+1,460,000
| +429% | +$21.6M |
|
|
DYAX
10
DELISTED
DYAX CORPORATION
DYAX
| $26M | 2.55% |
2,710,598
+147,924
| +6% | +$1.13M |
|
|
11
Zimmer Biomet
ZBH
$18.7B
| $25.2M | 2.47% |
+249,775
| New | +$24.4M |
|
|
SHPG
12
DELISTED
Shire pic
SHPG
| $21.2M | 2.08% |
90,000
+60,000
| +200% | +$10.4M |
|
|
WBA
13
DELISTED
Walgreens Boots Alliance
WBA
| $20.9M | 2.05% |
282,000
-22,419
| -7% | -$1.57M |
|
14
Xencor
XNCR
$1.44B
| $20.2M | 1.98% |
1,740,621
+251,949
| +17% | +$2.47M |
|
15
Heron Therapeutics
HRTX
$92.3M
| $20.1M | 1.98% |
1,634,555
-127,871
| -7% | -$1.53M |
|
|
TSRO
16
DELISTED
TESARO, Inc.
TSRO
| $19.8M | 1.94% |
636,956
-593,114
| -48% | -$15.8M |
|
|
NEPT
17
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $18.5M | 1.81% |
4,786
| – | – |
|
18
PTC Therapeutics
PTCT
$6.12B
| $17.6M | 1.72% |
671,736
| – | – |
|
|
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $15.7M | 1.54% |
371,469
+121,469
| +49% | +$4.46M |
|
|
EXAS
20
DELISTED
Exact Sciences
EXAS
| $15.3M | 1.51% |
901,250
-923,900
| -51% | -$12.7M |
|
21
Travere Therapeutics
TVTX
$5.13B
| $15M | 1.47% |
1,274,292
+230,000
| +22% | +$3.12M |
|
22
Acadia Pharmaceuticals
ACAD
$4.45B
| $14.8M | 1.45% |
653,000
-13,000
| -2% | -$271K |
|
23
Viatris
VTRS
$20.7B
| $14.6M | 1.43% |
282,500
+50,000
| +22% | +$2.46M |
|
|
RLYP
24
DELISTED
RELYPSA INC COM
RLYP
| $14.5M | 1.42% |
596,605
+415,405
| +229% | +$9.85M |
|
|
SGMO
25
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $12.2M | 1.2% |
800,000
| – | – |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2014 Portfolio in Review
As of Q2 2014, Perceptive Advisors held 173 positions worth $1.02B, up 7.1% from $952M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $52.9M of net new capital in Q2 2014, opening 45 new positions and adding to 25 existing holdings. Its largest new stake was Zimmer Biomet: 249,775 shares worth $25.2M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $17.8M trimmed.
- Perceptive Advisors's largest Q2 2014 buy was Zimmer Biomet: 249,775 shares worth $25.2M.
- Perceptive Advisors added most to QUESTCOR PHARMA INC in Q2 2014, an estimated $31.8M increase.
- Perceptive Advisors's biggest Q2 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $17.8M.
- Perceptive Advisors fully exited Endocyte, Inc. Common Stock in Q2 2014, selling an estimated $10.4M.
- Perceptive Advisors's ten largest holdings make up 47% of its $1.02B portfolio in Q2 2014.
- Perceptive Advisors opened 45 new positions and closed 56 in Q2 2014.
- Perceptive Advisors's portfolio value rose 7.1% quarter-over-quarter to $1.02B.
Based on Perceptive Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.